AMSTERDAM – Biotechnologist Kiadis Pharma is on track to receive conditional approval for its ATIR101 drug in Europe. Analysts from KBC Securities conclude this from a report from the company.
ATIR101 addresses key risk and limitations of HSCT in blood cancer, specifically, Graft-versus-Host-Disease (GVHD) and cancer relapse.
Kiadis announced that it had submitted its answers to questions from the European Medicines Agency (EMA) Committee on human use. That committee is likely to come up with an opinion on ATIR101 in June or July, say the market researchers. The goal of putting this medicine on the market in Europe before the end of this year would therefore be achievable.
KBC issues a buy recommendation and price target of 20.50 euros. The share was Thursday morning around 9.15 hours 4.6 percent higher at 9.49 euros.
Abaigael Schlomski is an accomplished economist and financial journalist with over a decade of experience in the industry. He is a regular contributor to EconomicInform, where he provides in-depth analysis and expert commentary on the latest economic trends and events. With a keen understanding of the financial markets and a talent for breaking down complex economic concepts for a general audience, Maurice is a trusted and respected voice in the field.
